Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of “Moderate Buy” by Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has earned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.9550.

A number of analysts recently weighed in on VYGR shares. Weiss Ratings restated a “sell (d)” rating on shares of Voyager Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Monday, September 15th. Finally, Wedbush cut their price objective on shares of Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th.

Voyager Therapeutics Stock Down 1.2%

NASDAQ VYGR opened at $4.22 on Friday. The stock’s 50-day simple moving average is $4.49 and its two-hundred day simple moving average is $3.70. Voyager Therapeutics has a twelve month low of $2.64 and a twelve month high of $7.44. The company has a market capitalization of $234.08 million, a price-to-earnings ratio of -2.28 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). The firm had revenue of $5.20 million during the quarter, compared to analysts’ expectations of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. On average, equities analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Nathan D. Jorgensen sold 7,666 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares of the company’s stock, valued at approximately $591,926.52. This trade represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.39% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VYGR. CWM LLC lifted its position in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after purchasing an additional 9,376 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Voyager Therapeutics in the second quarter worth $36,000. R Squared Ltd bought a new stake in Voyager Therapeutics during the 2nd quarter valued at $48,000. Los Angeles Capital Management LLC bought a new stake in Voyager Therapeutics during the 2nd quarter valued at $50,000. Finally, Privium Fund Management B.V. purchased a new stake in Voyager Therapeutics during the 1st quarter valued at $73,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.